Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,859 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo IV infusion Clear all
Completed Phase 4 Interventional Results available

Intravenous Acetaminophen in Craniotomy

NCT01598701
View directory record Official record
Conditions
Postoperative Pain
Interventions
Acetaminophen, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

ATG-GCSF in New Onset Type 1 Diabetes

NCT02215200
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 3 Interventional

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

NCT03274492
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Vincristine Placebo, Prednisone, Polatuzumab vedotin Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
49
States / cities
Birmingham, Alabama • Daphne, Alabama • Duarte, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 3 Interventional Results available

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

NCT00783718
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
102
States / cities
Birmingham, Alabama • Los Angeles, California • Montebello, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

NCT01115920
View directory record Official record
Conditions
Healthy
Interventions
MTP-131 (Bendavia™)
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Oct 13, 2026, 1:16 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

NCT03969004
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Cemiplimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
40
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 1 Interventional

Alirocumab in Patients with Sepsis

NCT05469347
View directory record Official record
Conditions
Sepsis
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
Jonathan Sevransky
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

NCT02289690
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Veliparib, Carboplatin, Etoposide, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
9
States / cities
Scottsdale, Arizona • Aurora, Colorado • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 4 Interventional Results available

A Comparison of Intra-op Ketamine vs Placebo in Patients Having Spinal Fusion

NCT02424591
View directory record Official record
Conditions
Postoperative Pain
Interventions
Ketamine, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

NCT00110591
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 140
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 1 Interventional

Safety, Efficacy and Pharmacokinetics of ALD403

NCT01772524
View directory record Official record
Conditions
Migraine
Interventions
ALD403, Placebo
Biological · Drug
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Phoenix, Arizona • Anaheim, California • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 1Phase 2 Interventional

YSPSL for Prevention of Delayed Graft Function Part B

NCT00298168
View directory record Official record
Conditions
Kidney Diseases
Interventions
YSPSL, placebo
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Oct 13, 2026, 1:16 PM EDT
Withdrawn Phase 3 Interventional

Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer

NCT02929576
View directory record Official record
Conditions
Breast Cancer
Interventions
Enzalutamide, Placebo, Paclitaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
6
States / cities
Topeka, Kansas • Metairie, Louisiana • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 13, 2026, 1:16 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

NCT05322590
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Neuropathy
Interventions
BXQ-350, Placebo
Drug · Other
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
12
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 13, 2026, 1:16 PM EDT
Withdrawn Not applicable Interventional

Treatment of Postoperative Pain After Total Knee Arthroplasy Using Intravenous Lidocaine Infusion

NCT00616850
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Continuous femoral catheter block, Lidocaine, Preservative free normal saline
Procedure · Drug · Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 13, 2026, 1:16 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Effectiveness Of Intravenous TXA on Reducing Perioperative Blood Loss For Patients Undergoing PAO

NCT03823417
View directory record Official record
Conditions
Bleeding
Interventions
Tranexamic Acid, Normal saline
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

NCT04385368
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab + SoC chemotherapy, Placebo + SoC chemotherapy
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Long Beach, California • Santa Rosa, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Ghrelin in Healthy and Frail Older Women

NCT00520884
View directory record Official record
Conditions
Frailty
Interventions
Ghrelin Infusion - Healthy, Ghrelin Infusion - Frail, Placebo Infusion -Healthy, Placebo Infusion - Frail
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
70 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

NCT00605475
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Canakinumab, Placebo, Metformin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Miami, Florida • MD, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of MGD010 in Healthy Subjects

NCT02376036
View directory record Official record
Conditions
Healthy Subjects
Interventions
MGD010, Placebo, Hepatitis A vaccine
Drug · Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 50 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 3 Interventional

Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery

NCT06021457
View directory record Official record
Conditions
Post-Operative Complications in Cardiac Surgery
Interventions
RBT-1, Placebo
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Huntsville, Alabama • La Jolla, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 13, 2026, 1:16 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND)
Biological · Other · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 13, 2026, 1:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers

NCT02707107
View directory record Official record
Conditions
Serious Gram-negative Infections
Interventions
Intravenous infusions of WCK 5222, Placebo
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 13, 2026, 1:16 PM EDT
Terminated Phase 2 Interventional

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

NCT04265534
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
Interventions
Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Placebo, Folic acid 400 -1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg
Drug · Biological · Dietary Supplement
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 13, 2026, 1:16 PM EDT